cbdMD Past Earnings Performance
Past criteria checks 0/6
cbdMD's earnings have been declining at an average annual rate of -11%, while the Pharmaceuticals industry saw earnings declining at 0.4% annually. Revenues have been growing at an average rate of 2.1% per year.
Key information
-11.0%
Earnings growth rate
37.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 2.1% |
| Return on equity | -701.4% |
| Net Margin | -118.9% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How cbdMD makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 22 | -26 | 15 | 0 |
| 31 Dec 23 | 23 | -24 | 16 | 0 |
| 30 Sep 23 | 24 | -27 | 17 | 0 |
| 30 Jun 23 | 26 | -26 | 21 | 0 |
| 31 Mar 23 | 29 | -56 | 23 | 0 |
| 31 Dec 22 | 32 | -59 | 28 | 0 |
| 30 Sep 22 | 35 | -74 | 33 | 1 |
| 30 Jun 22 | 37 | -63 | 38 | 1 |
| 31 Mar 22 | 39 | -29 | 44 | 1 |
| 31 Dec 21 | 41 | -37 | 45 | 1 |
| 30 Sep 21 | 44 | -26 | 43 | 1 |
| 30 Jun 21 | 46 | -28 | 41 | 1 |
| 31 Mar 21 | 46 | -38 | 36 | 1 |
| 31 Dec 20 | 44 | -10 | 37 | 1 |
| 30 Sep 20 | 42 | 12 | 39 | 0 |
| 30 Jun 20 | 40 | 31 | 41 | 0 |
| 31 Mar 20 | 37 | 15 | 45 | 0 |
| 31 Dec 19 | 33 | -32 | 39 | 0 |
| 30 Sep 19 | 24 | -45 | 29 | 0 |
| 30 Jun 19 | 8 | -60 | 15 | 0 |
| 31 Mar 19 | 3 | -35 | 6 | 0 |
| 31 Dec 18 | 0 | -2 | 2 | 0 |
| 30 Sep 18 | 0 | -2 | 2 | 0 |
Quality Earnings: YCBD.PRA is currently unprofitable.
Growing Profit Margin: YCBD.PRA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: YCBD.PRA is unprofitable, and losses have increased over the past 5 years at a rate of 11% per year.
Accelerating Growth: Unable to compare YCBD.PRA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: YCBD.PRA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.9%).
Return on Equity
High ROE: YCBD.PRA has a negative Return on Equity (-701.44%), as it is currently unprofitable.